Gossamer Bio (NASDAQ:GOSS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research note released on Monday, Benzinga reports. They currently have a $10.00 target price on the stock.

Other analysts have also issued research reports about the company. Piper Sandler restated an overweight rating and set a $15.00 target price on shares of Gossamer Bio in a report on Wednesday, March 27th. Wedbush restated an outperform rating and set a $4.00 target price on shares of Gossamer Bio in a report on Wednesday, May 8th. Finally, The Goldman Sachs Group lowered their target price on Gossamer Bio from $9.00 to $8.00 and set a buy rating for the company in a report on Wednesday, March 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $7.65.

Gossamer Bio Stock Down 4.7 %

Shares of NASDAQ GOSS opened at $0.64 on Monday. The company has a debt-to-equity ratio of 7.37, a quick ratio of 7.13 and a current ratio of 7.13. The firm has a market capitalization of $144.44 million, a price-to-earnings ratio of -0.60 and a beta of 1.84. The stock has a 50 day moving average price of $0.94 and a 200 day moving average price of $0.95. Gossamer Bio has a 52-week low of $0.45 and a 52-week high of $1.88.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). Sell-side analysts expect that Gossamer Bio will post -0.35 earnings per share for the current year.

Insider Activity

In other news, CEO Faheem Hasnain sold 23,172 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $1.16, for a total transaction of $26,879.52. Following the completion of the sale, the chief executive officer now owns 120,293 shares in the company, valued at approximately $139,539.88. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 33,620 shares of company stock worth $39,682. Insiders own 5.00% of the company’s stock.

Hedge Funds Weigh In On Gossamer Bio

Hedge funds have recently made changes to their positions in the company. Sivia Capital Partners LLC acquired a new position in shares of Gossamer Bio in the 1st quarter valued at $29,000. SG Americas Securities LLC acquired a new position in shares of Gossamer Bio in the 1st quarter valued at $34,000. Bank of New York Mellon Corp increased its position in shares of Gossamer Bio by 178.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 91,246 shares of the company’s stock valued at $76,000 after acquiring an additional 58,428 shares during the period. Financial Advocates Investment Management increased its position in shares of Gossamer Bio by 35.0% in the 4th quarter. Financial Advocates Investment Management now owns 98,350 shares of the company’s stock valued at $90,000 after acquiring an additional 25,500 shares during the period. Finally, Citigroup Inc. increased its position in shares of Gossamer Bio by 9,916.9% in the 3rd quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock valued at $164,000 after acquiring an additional 194,768 shares during the period. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.